Canada markets close in 1 hour 43 minutes

Arch Biopartners Inc. (ACHFF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.0640+0.0140 (+0.68%)
As of 10:55AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close2.0500
Open2.0640
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.0640 - 2.0640
52 Week Range1.8900 - 3.3800
Volume1,700
Avg. Volume3,867
Market Cap129.716M
Beta (5Y Monthly)1.07
PE Ratio (TTM)206.40
EPS (TTM)0.0100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.75
  • GlobeNewswire

    Shares for Interest Debt Settlement; Grants Options

    TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $201,459 in interest accrued up to September 30, 2022 on all five of the deferred convertible notes outstanding and disclosed in the Company’s financial statements (the “Notes”). The shares for debt settlement is pending final approval from the TSX Venture Exchange (T

  • GlobeNewswire

    Arch Biopartners Adds Farris Smith as a Strategic Advisor

    TORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, welcomed Mr. Farris Smith of Novo Nordisk Canada Inc as a Strategic Advisor for general corporate activity and business development of the Company’s drug candidates. Mr. Farris Smith started his career with AP Moller in 2001 and jo

  • GlobeNewswire

    Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

    TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with novel therapeutics, announced today that the Company has added Dr. David Luke as a Strategic Advisor for the clinical trial development of the Company’s drug candidates. Dr. Luke previously held a variety of positions in the pharma industry, including approximately twenty years at Pfizer Inc, where he wa